Viking Therapeutics (VKTX) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Viking Therapeutics (VKTX) Misses Q1 EPS by 8c

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

April 23, 2025 4:05 PM EDT

Conference call scheduled for 4:30 p.m. ET today

Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25

Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25

Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735

Strong Quarter-End Cash Position of $852 Million

SAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a... More